182 related articles for article (PubMed ID: 21568878)
1. Novel folate-hydroxamate based antimetabolites: synthesis and biological evaluation.
Carrasco MP; Enyedy EA; Krupenko NI; Krupenko SA; Nuti E; Tuccinardi T; Santamaria S; Rossello A; Martinelli A; Santos MA
Med Chem; 2011 Jul; 7(4):265-74. PubMed ID: 21568878
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.
Santos MA; Enyedy EA; Nuti E; Rossello A; Krupenko NI; Krupenko SA
Bioorg Med Chem; 2007 Feb; 15(3):1266-74. PubMed ID: 17127067
[TBL] [Abstract][Full Text] [Related]
3. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF
J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference ¹H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives.
Mohebbi S; Falcón-Pérez JM; González E; Millet O; Mato JM; Kobarfard F
Chem Pharm Bull (Tokyo); 2012; 60(1):70-8. PubMed ID: 22223377
[TBL] [Abstract][Full Text] [Related]
6. Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Gangjee A; Zeng Y; McGuire JJ; Kisliuk RL
J Med Chem; 2000 Aug; 43(16):3125-33. PubMed ID: 10956221
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.
Tian C; Wang M; Han Z; Fang F; Zhang Z; Wang X; Liu J
Eur J Med Chem; 2017 Sep; 138():630-643. PubMed ID: 28711701
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.
Al-Rashood ST; Aboldahab IA; Nagi MN; Abouzeid LA; Abdel-Aziz AA; Abdel-Hamide SG; Youssef KM; Al-Obaid AM; El-Subbagh HI
Bioorg Med Chem; 2006 Dec; 14(24):8608-21. PubMed ID: 16971132
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
Zhou X; Lin K; Ma X; Chui WK; Zhou W
Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Fang H; Xu W
Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
[TBL] [Abstract][Full Text] [Related]
11. Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
Gao T; Zhang C; Shi X; Guo R; Zhang K; Gu J; Li L; Li S; Zheng Q; Cui M; Cui M; Gao X; Liu Y; Wang L
Eur J Med Chem; 2019 Sep; 178():329-340. PubMed ID: 31200235
[TBL] [Abstract][Full Text] [Related]
12. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
13. Dihydrofolate reductase inhibition effect of 5-substituted pyrido[2,3-d]pyrimidines: Synthesis, antitumor activity and molecular modeling study.
Abdelaziz OA; El Husseiny WM; Selim KB; Eisa HM
Bioorg Chem; 2019 Sep; 90():103076. PubMed ID: 31260878
[TBL] [Abstract][Full Text] [Related]
14. 2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes.
Piras S; Carta A; Briguglio I; Corona P; Paglietti G; Luciani R; Costi MP; Ferrari S
Eur J Med Chem; 2014 Mar; 75():169-83. PubMed ID: 24531230
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate.
Yang PM; Lin JH; Huang WY; Lin YC; Yeh SH; Chen CC
Biochem Biophys Res Commun; 2010 Jan; 391(3):1396-9. PubMed ID: 20026300
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: the Abbott experience.
Curtin M; Glaser K
Curr Med Chem; 2003 Nov; 10(22):2373-92. PubMed ID: 14529480
[TBL] [Abstract][Full Text] [Related]
18. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro biological activity of new deaza analogues of folic acid, aminopterin, and methotrexate with an L-ornithine side chain.
Rosowsky A; Forsch RA; Bader H; Freisheim JH
J Med Chem; 1991 Apr; 34(4):1447-54. PubMed ID: 2016722
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
Gangjee A; Zeng Y; McGuire JJ; Kisliuk RL
J Med Chem; 2002 Nov; 45(23):5173-81. PubMed ID: 12408727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
